低分子肝素已经代替普通肝素用于大多数深静脉血栓患者的治疗中,但在有症状的急性肺栓塞治疗中的地位尚未明确。Fondaparinx是一种合成的Xa因子选择性抗血栓新药,其疗效与低分子肝素相似,同样可以同一剂量、每日一次、皮下注射使用,勿需监测凝血时间。 方法 采用随机、开放、对照的研究方法连续观察2213例18岁以上的需要抗血栓治疗的有症状的急性肺栓塞患者,随机分为Fondaparinx Low molecular weight heparin has been used in the treatment of most patients with deep vein thrombosis instead of unfractionated heparin, but its status in the treatment of symptomatic acute pulmonary embolism has not been clarified yet. Fondaparinx is a synthetic Xa factor selective anti-thrombotic drug, its efficacy and low molecular weight heparin similar, the same dose, once daily, subcutaneous injection, do not need to monitor the clotting time. Methods A randomized, open and controlled study was conducted to continuously observe 2213 patients with symptomatic acute pulmonary embolism who needed anti-thrombosis over the age of 18 and were randomly divided into Fondaparinx